Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.

Archive ouverte

El H., Hajj | El-Sabban, M. | Hasegawa, H. | Zaatari, G. | Ablain, J. | S.T., Saab | Janin, A. | Mahfouz, R. | Nasr, R. | Kfoury, Y. | Nicot, C. | Hermine, O. | Hall, W. | de Thé, H. | Bazarbachi, A.

Edité par CCSD ; Rockefeller University Press -

International audience. Chronic HTLV-I (human T cell lymphotropic virus type I) infection may cause adult T cell leukemia/lymphoma (ATL), a disease with dismal long-term prognosis. The HTLV-I transactivator, Tax, initiates ATL in transgenic mice. In this study, we demonstrate that an As2O3 and IFN-alpha combination, known to trigger Tax proteolysis, cures Tax-driven ATL in mice. Unexpectedly, this combination therapy abrogated initial leukemia engraftment into secondary recipients, whereas the primary tumor bulk still grew in the primary hosts, only to ultimately abate later on. This loss of initial transplantability required proteasome function. A similar regimen recently yielded unprecedented disease control in human ATL. Our demonstration that this drug combination targeting Tax stability abrogates tumor cell immortality but not short-term growth may foretell a favorable long-term efficiency of this regimen in patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion